This assessment shows improved renal function and reduced proteinuria in IgA nephropathy, indicating potential benefits of nefecon as first-line therapy.
Nefecon, the gut-targeted formulation of budesonide, designed to modulate gut-associated lymphoid tissue and suppress the synthesis of galactose-deficient IgA1, has shown significant efficacy in reducing proteinuria and preserving renal function in patients with IgA nephropathy (IgAN). However, real-world evidence regarding its efficacy and safety as an initial therapeutic option in the broader IgAN population remains limited.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: